SARS-CoV-2/COVID-19 in multiple sclerosis patients receiving disease-modifying therapy
| Autor: | Paweł Sowa, Monika Adamczyk-Sowa, Katarzyna Kubicka-Bączyk, Wojciech Bartman, Hubert Mado, Barbara Sobala-Szczygieł, Jerzy Jaroszewicz |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Adult
medicine.medical_specialty Neurology Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Disease macromolecular substances Article Multiple sclerosis 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Multiple Sclerosis Relapsing-Remitting Internal medicine medicine Disease-modifying therapy Humans Glatiramer acetate Immunosuppressive effect Dimethyl fumarate business.industry SARS-CoV-2 COVID-19 General Medicine MS Middle Aged medicine.disease COVID-19 Drug Treatment chemistry 030220 oncology & carcinogenesis Surgery Female Neurology (clinical) business 030217 neurology & neurosurgery Immunosuppressive Agents medicine.drug |
| Zdroj: | Clinical Neurology and Neurosurgery |
| ISSN: | 1872-6968 0303-8467 |
| Popis: | Highlights • MS-related disability is an independent risk factor for COVID-19 severity. • Most likely, disease-modifying therapy does not affect the severity of COVID-19. • Special caution should be applied when administering DMT causing lymphopenia in patients with MS and COVID-19. At the end of 2019, the COVID-19 pandemic began, which at the time of writing continues to be a serious problem for many areas of medicine, including neurology. Since patients with multiple sclerosis (MS) often exhibit motor disability and receive disease-modifying therapy (DMT), which has an immunosuppressive effect, it is plausible that this will affect the susceptibility of MS patients to COVID-19, as well as the course of this disease. However, current data indicate that the use of DMT does not cause negative prognosis in COVID-19 sufferers, but the motor disability progression associated with MS does. In this study, we present the case reports of 4 patients with relapsing-remitting MS, who developed COVID-19, and despite the use of DMT the course of the disease was mild. Two patients were treated with dimethyl fumarate, one with Interferon β1b and one with glatiramer acetate. One of the patients using dimethyl fumarate had lymphopenia. All patients had symptoms of COVID-19 from the nervous system, the most frequent being headache, which occurred in all patients. The aim of this article is to present a case series of four patients with MS and COVID-19, and to discuss the available literature on COVID-19 in patients with MS, with particular consideration of the impact of DMT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect